MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: Baptist Medical Center in Florida adopts endomicroscopy with Cellvizio

Transparency directive : regulatory news

23/03/2015 18:06

Press release

    BAPTIST MEDICAL CENTER IN FLORIDA ADOPTS ENDOMICROSCOPY WITH CELLVIZIO TO
          IMPROVE CARE FOR PATIENTS WITH BILIARY AND PANCREATIC DISEASES

Baptist Medical Center is a regional center of excellence for biio-pancreatic
                                   disorders

PARIS, March 23rd 2015- Mauna Kea Technologies (Euronext: MKEA, FR0010609263),
inventor of Cellvizio(r), the multidisciplinary confocal laser endomicroscopy
platform, today announced that Baptist Medical Center in Jacksonville, Florida,
a leading medical center in the southeastern United States, has adopted the
Cellvizio technology platform to perform enhanced procedures in the field of
biliary and pancreatic disorders including probe-based confocal laser
endomicroscopy (pCLE) and needle-based confocal laser endomicroscopy (nCLE).

"Baptist Medical Center is a leading center for treatment of pancreatic cysts
and biliary strictures. We currently perform more than 2,000 pancreatic and
1,500 biliary procedures each year. The Cellvizio technology provides us with
fast, accurate information about the nature of pancreatic cysts and biliary
strictures with very high specificity and safety," said Dr. Jose Nieto, chairman
of the Advanced Therapeutic Endoscopy Center, Borland Groover Clinic at Baptist
Medical Center. "The use of pCLE and nCLE with Cellvizio has changed the way I
perform these procedures, and we are very optimistic about advancing this
technology for use in other areas to diagnose a broader range of health problems
in the digestive systems".

Procedures used to diagnose pancreatic cysts typically include the use of
endoscopic ultrasound fine needle aspiration (EUSFNA) and cytology, while
procedures to diagnose biliary strictures involve the use of specialty
endoscopes and catheters. In multiple clinical studies, the use of Cellvizio has
been shown to help diagnose pancreatic cysts and biliary strictures with
significantly higher levels of sensitivity and specificity, helping doctors to
advance patients to appropriate care more rapidly while reducing or eliminating
the need for more invasive procedures to confirm a diagnosis. In some cases,
Cellvizio can even eliminate the need for unnecessary surgeries, which are very
traumatic to patients and costly to the healthcare system.

"In recent months we have presented new data from a range of clinical studies
showing the important advantages Cellvizio offers in the treatment of pancreatic
cysts and biliary strictures. We are progressively seeing adoption of our
technology by the leading community hospitals and regional medical centers
treating a high number of patients with such disorders. We are especially
pleased that renowned specialists in this therapeutic area such as Dr José
Nieto are adopting endomicroscopy to bring these important advantages to their
patients," said Sacha Loiseau, Ph.D, CEO and founder of Mauna Kea
Technologies.

For more information on the use of Cellvizio at Baptist Medical Center, view a
recent TV report here.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on leading
innovation in endomicroscopy and optical biopsy. The company designs, develops
and markets innovative tools to visualize and detect cell abnormalities in real
time during standard gastrointestinal and pulmonary endoscopy procedures. The
company's flagship product, Cellvizio(r), a probe-based Confocal Laser
Endomicroscopy (pCLE) system, provides physicians and researchers with
high-resolution cellular imaging of internal tissues. Large- scale,
international, multi-center clinical trials have demonstrated Cellvizio's
ability to help physicians to more accurately detect early forms of diseases
and make immediate treatment decisions. Designed to help physicians in their
diagnoses, provide patients with better treatment and reduce hospital costs,
the Cellvizio system can be used with practically all endoscopes. Cellvizio has
510(k) clearance from the United States Food and Drug Administration and CE
Marking in the European Union for use in the gastrointestinal tract and the
urinary and respiratory systems, for endoscopic exploration of the biliary and
pancreatic ducts, and for fine-needle aspiration procedures. Cellvizio also
obtained SFDA regulatory approval in China and MHLW approval in Japan.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies            France and Europe
Eric Cohen                        NewCap
Vice President Finance            Investor Relations & Financial Communication
Tel: +33 (0)1 70 08 09 70         Florent Alba / Pierre Laurent
investor-vpf@maunakeatech.com     Tel: +33 (0)1 44 71 94 94
                                  maunakea@newcap.fr

United States
Berry & Company Public Relations
US - Public Relations Bill Berry
Tel: +1 212 253 8881
bberry@berrypr.com

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: Baptist Medical Center in Florida adopts endomicroscopy with Cellvizio

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories